Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8556MR)

This product GTTS-WQ8556MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8556MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13097MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ4296MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ6416MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ1832MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ8129MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ4254MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ12239MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ8700MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW